Population-based cohort study: proton pump inhibitor use during pregnancy in Sweden and the risk of maternal and neonatal adverse events.
Logistic regression
Maternal and neonatal health
Pregnancy
Proton pump inhibitors
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
20 12 2022
20 12 2022
Historique:
received:
12
08
2022
accepted:
21
11
2022
entrez:
20
12
2022
pubmed:
21
12
2022
medline:
23
12
2022
Statut:
epublish
Résumé
Approximately half of all women suffer from heartburn at some stage during pregnancy. The most effective treatment is proton pump inhibitors, but the safety of use during pregnancy cannot be guaranteed. This study aimed to elucidate the effect of proton pump inhibitors on the risk of pre-eclampsia, gestational diabetes mellitus, preterm birth, an Apgar score at 5 min below 7, and a child being small or large for its gestational age. This Swedish population-based study included 1,089,514 live singleton deliveries between July 2006 and December 2016 in Sweden. Multiple logistic regression was used to model the outcomes as a function of the covariates. Results were presented as odds ratios with 95% confidence intervals. In 1.4% of all pregnancies, the mother used proton pump inhibitors in the period from 3 months before the last menstrual period up to delivery. The use of proton pump inhibitors was associated with higher odds of pre-eclampsia (odds ratio = 1.19, 1.10-1.29), gestational diabetes mellitus (odds ratio = 1.29, 1.16-1.43), preterm birth (odds ratio = 1.23, 1.14-1.32), and small for gestational age (odds ratio = 1.27, 1.16-1.40) and lower odds of large for gestational age (odds ratio = 0.84, 0.77-0.91). No significant association was found with a low Apgar score 5 min after birth. Proton pump inhibitor use was associated with a higher risk of pre-eclampsia, gestational diabetes, preterm birth, and being born small for gestational age.
Sections du résumé
BACKGROUND
Approximately half of all women suffer from heartburn at some stage during pregnancy. The most effective treatment is proton pump inhibitors, but the safety of use during pregnancy cannot be guaranteed. This study aimed to elucidate the effect of proton pump inhibitors on the risk of pre-eclampsia, gestational diabetes mellitus, preterm birth, an Apgar score at 5 min below 7, and a child being small or large for its gestational age.
METHODS
This Swedish population-based study included 1,089,514 live singleton deliveries between July 2006 and December 2016 in Sweden. Multiple logistic regression was used to model the outcomes as a function of the covariates. Results were presented as odds ratios with 95% confidence intervals.
RESULTS
In 1.4% of all pregnancies, the mother used proton pump inhibitors in the period from 3 months before the last menstrual period up to delivery. The use of proton pump inhibitors was associated with higher odds of pre-eclampsia (odds ratio = 1.19, 1.10-1.29), gestational diabetes mellitus (odds ratio = 1.29, 1.16-1.43), preterm birth (odds ratio = 1.23, 1.14-1.32), and small for gestational age (odds ratio = 1.27, 1.16-1.40) and lower odds of large for gestational age (odds ratio = 0.84, 0.77-0.91). No significant association was found with a low Apgar score 5 min after birth.
CONCLUSIONS
Proton pump inhibitor use was associated with a higher risk of pre-eclampsia, gestational diabetes, preterm birth, and being born small for gestational age.
Identifiants
pubmed: 36539798
doi: 10.1186/s12916-022-02673-x
pii: 10.1186/s12916-022-02673-x
pmc: PMC9768950
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
492Subventions
Organisme : Vetenskapsrådet
ID : 2020-01058
Informations de copyright
© 2022. The Author(s).
Références
BMJ. 2017 Feb 8;356:j1
pubmed: 28179267
Adv Neonatal Care. 2015 Dec;15(6):377-85
pubmed: 26317856
Gastroenterology. 2006 Jul;131(1):278-82
pubmed: 16831610
Am J Ther. 2003 Sep-Oct;10(5):370-6
pubmed: 12975722
N Engl J Med. 2010 Nov 25;363(22):2114-23
pubmed: 21105793
Br J Obstet Gynaecol. 1998 Aug;105(8):882-9
pubmed: 9746382
J Am Acad Nurse Pract. 2005 Jan;17(1):4-8
pubmed: 15679877
World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):180-185
pubmed: 28828196
Curr Gastroenterol Rep. 2018 May 16;20(6):27
pubmed: 29767318
Am J Perinatol. 2021 Dec;38(14):1519-1525
pubmed: 32620021
Therap Adv Gastroenterol. 2016 Sep;9(5):671-8
pubmed: 27582879
Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
Am J Epidemiol. 1999 Sep 1;150(5):476-81
pubmed: 10472947
Am J Obstet Gynecol. 2018 Oct;219(4):388.e1-388.e17
pubmed: 30055127
Gut Microbes. 2017 Jul 4;8(4):351-358
pubmed: 28118083
Health Qual Life Outcomes. 2012 Dec 05;10:146
pubmed: 23216805
Diabetes Care. 2004 Jan;27 Suppl 1:S88-90
pubmed: 14693936
Hypertension. 2019 May;73(5):1097-1103
pubmed: 30827143
Dig Dis Sci. 2002 Jul;47(7):1526-9
pubmed: 12141812
Dtsch Arztebl Int. 2018 Apr 20;115(16):276-283
pubmed: 29739495
Cochrane Database Syst Rev. 2015 Sep 19;(9):CD011379
pubmed: 26384956
Aliment Pharmacol Ther. 2012 May;35(10):1190-8
pubmed: 22443179
Aliment Pharmacol Ther. 2005 Feb 1;21(3):269-75
pubmed: 15691301
Am J Obstet Gynecol. 2010 Feb;202(2):164.e1-8
pubmed: 20113692
J Antimicrob Chemother. 2022 Apr 27;77(5):1461-1467
pubmed: 35233608
Cochrane Database Syst Rev. 2017 Mar 16;3:CD011969
pubmed: 28301676
Reprod Biol Endocrinol. 2022 Feb 7;20(1):30
pubmed: 35130922
Aliment Pharmacol Ther. 2021 Jul;54(2):129-143
pubmed: 34114655
Int J Clin Pharm. 2015 Oct;37(5):709-16
pubmed: 26100836
Gut. 2016 May;65(5):740-8
pubmed: 26657899
Semin Immunopathol. 2020 Aug;42(4):487-499
pubmed: 32797272
PLoS One. 2013;8(2):e56060
pubmed: 23418510
Epidemiology. 1998 May;9(3):279-85
pubmed: 9583419
BMJ Open Diabetes Res Care. 2016 Aug 11;4(1):e000221
pubmed: 27547412
Best Pract Res Clin Gastroenterol. 2020 Feb - Apr;44-45:101671
pubmed: 32359685
Aliment Pharmacol Ther. 2020 Feb;51(4):410-420
pubmed: 31909512
Nutr Rev. 2015 Aug;73 Suppl 1:32-40
pubmed: 26175488
Aliment Pharmacol Ther. 2005 Nov 1;22(9):749-57
pubmed: 16225482
Aliment Pharmacol Ther. 1999 Aug;13(8):1085-9
pubmed: 10468685
Gut Pathog. 2022 Dec 16;14(1):47
pubmed: 36527125
Biomed Res Int. 2015;2015:217047
pubmed: 26539470
BMJ Open. 2020 Nov 26;10(11):e040473
pubmed: 33243802
Front Immunol. 2014 Nov 27;5:595
pubmed: 25505898
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Therap Adv Gastroenterol. 2018 May 30;11:1756284818777943
pubmed: 29872455
JAMA Netw Open. 2021 Sep 1;4(9):e2124339
pubmed: 34491354
Endocr Regul. 2000 Mar;34(1):33-6
pubmed: 10808251
Dig Dis Sci. 2012 Mar;57(3):699-705
pubmed: 22038541
Lancet. 2005 Feb 26-Mar 4;365(9461):785-99
pubmed: 15733721
Acta Obstet Gynecol Scand. 2003 Jun;82(6):491-2
pubmed: 12780418
Acta Paediatr. 1996 Jul;85(7):843-8
pubmed: 8819552
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791